Response criteria for intraocular retinoblastoma: RB-RECIST.
Standardized guidelines for assessing tumor response to therapy are essential for designing and conducting clinical trials. The Response Evaluation Criteria In Solid Tumors (RECIST) provide radiological standards for assessment of solid tumors. However, no such guidelines exist for the evaluation of intraocular cancer, and ocular oncology clinical trials have largely relied on indirect measures of therapeutic response-such as progression-free survival-to evaluate the efficacy of treatment agents. Herein, we propose specific criteria for evaluating treatment response of retinoblastoma, the most common pediatric intraocular cancer, and emphasize a multimodal imaging approach for comprehensive assessment of retinoblastoma tumors in clinical trials.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Retinoblastoma
- Retinal Neoplasms
- Response Evaluation Criteria in Solid Tumors
- Oncology & Carcinogenesis
- Multimodal Imaging
- Humans
- 3213 Paediatrics
- 3211 Oncology and carcinogenesis
- 1114 Paediatrics and Reproductive Medicine
- 1112 Oncology and Carcinogenesis
Citation
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Retinoblastoma
- Retinal Neoplasms
- Response Evaluation Criteria in Solid Tumors
- Oncology & Carcinogenesis
- Multimodal Imaging
- Humans
- 3213 Paediatrics
- 3211 Oncology and carcinogenesis
- 1114 Paediatrics and Reproductive Medicine
- 1112 Oncology and Carcinogenesis